Sarcomere Variants: Cardiac Risk Between HCM & No Mutation

The question of whether family members of someone diagnosed with hypertrophic cardiomyopathy (HCM) are at increased risk is a deeply personal one, and recent findings offer a more nuanced understanding. Whereas a genetic link is well established in many HCM cases, the degree of risk for relatives carrying a known gene variant isn’t uniform. Fresh data suggest that relatives with a pathogenic sarcomere gene variant – a change in a gene that affects the heart muscle – face a lower risk of serious cardiac events than those *with* HCM, but a higher risk than relatives who don’t carry the variant. This clarifies a previously somewhat ambiguous area of risk assessment.

Understanding Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy is a condition where the heart muscle becomes abnormally thick. This thickening can produce it harder for the heart to pump blood and can lead to symptoms like shortness of breath, chest pain, and palpitations. In some cases, it can cause sudden cardiac death. It’s considered a genetic cardiomyopathy, meaning it’s often caused by mutations in genes that control heart muscle function. However, not everyone with a gene mutation will develop the condition – a phenomenon known as incomplete penetrance – and the severity can vary greatly, even within the same family.

Approximately 60% of familial HCM cases are linked to mutations in sarcomeric genes, which are responsible for the proteins that make up the heart’s contractile units. Research published in the Journal of Cardiovascular Imaging in July 2025 highlights the importance of genetic testing in understanding HCM, not just for diagnosis but also for predicting outcomes and guiding treatment. The study emphasizes that genetic testing can help identify individuals at risk, even before symptoms appear, and facilitate cascade testing within families.

The Genetic Landscape of HCM

The genetic basis of HCM is complex. While sarcomeric mutations are the most common cause, other genetic factors can also play a role. A review article in the same journal notes that mitochondrial DNA variants and other genetic modifiers can contribute to the wide range of symptoms and severity seen in HCM patients. Mitochondrial DNA relates to the energy-producing parts of cells, and variations here can affect heart muscle function. This complexity explains why predicting the course of the disease in individual family members can be challenging.

What Does This Indicate for Families?

The recent findings suggest that simply carrying a gene variant doesn’t automatically equate to developing significant heart problems. The risk appears to fall somewhere between those who have the full-blown disease and those who don’t have the genetic mutation at all. This is critical because it informs how families approach genetic screening and monitoring. Cascade testing – where family members of an affected individual are tested for the same genetic mutation – remains a crucial part of HCM management, but the results require to be interpreted carefully.

For example, a relative testing positive for a known HCM-causing mutation might benefit from more frequent cardiac check-ups, including echocardiograms and potentially cardiac MRI scans, to monitor for early signs of the disease. However, the intensity of monitoring would likely be less than that recommended for someone already diagnosed with HCM. It’s crucial to remember that these are guidelines, and individual management plans should be determined by a qualified cardiologist.

Beyond Sarcomeric Genes: A Broader View

It’s also important to note that not all HCM is caused by identifiable genetic mutations. Research published in Circulation highlights the differences in disease trajectory and outcomes between those with sarcomere gene variants and those without. This suggests that other genetic and environmental factors likely contribute to the development of HCM in some individuals. This underscores the need for a comprehensive approach to risk assessment, considering not just genetic testing but also clinical evaluation and lifestyle factors.

Risk Context and Absolute vs. Relative Risk

When discussing risk, it’s vital to understand the difference between absolute and relative risk. Relative risk compares the risk of an event in one group to the risk in another. Absolute risk, represents the actual probability of an event occurring. For example, a statement that a genetic variant “doubles” the risk of a cardiac event is a relative risk. The absolute risk might still be low, even if it’s doubled. Without knowing the baseline risk, it’s difficult to fully appreciate the significance of a relative risk increase.

What Comes Next: Ongoing Research and Clinical Practice

The field of HCM genetics is rapidly evolving. Emerging therapies, including myosin inhibitors (drugs that help the heart muscle relax) and gene-editing approaches, offer potential new ways to treat the underlying causes of the disease. However, these therapies are still under investigation and are not yet widely available. Ongoing research is focused on identifying additional genes involved in HCM, refining risk prediction models, and developing more effective treatments.

For families concerned about HCM, the most important step is to consult with a cardiologist specializing in genetic cardiomyopathies. They can provide personalized risk assessment, recommend appropriate genetic testing, and develop a management plan tailored to individual needs. Staying informed about the latest research and guidelines is also crucial. Reliable sources of information include the American Heart Association and the National Heart, Lung, and Blood Institute.

The process of understanding and managing HCM is ongoing. As our knowledge of the genetic and clinical factors involved continues to grow, we can expect even more precise and personalized approaches to prevention and treatment.